12. 15. 2020, Axine Winter 2020 Company Update
Establishing a Foundation for Sustained Growth & Momentum
Despite the challenges presented by COVID-19, Axine made significant progress in 2020. In particular, we worked with leading pharmaceutical and chemical manufacturers worldwide to validate and implement our new standard for the on-site treatment of the toughest organic pollutants in industrial wastewater. Whether it was manufacturing effluent contaminated with Active Pharmaceutical Ingredients (APIs) such as antibiotics, antiparasitics or steroids; solvents; or other complex organics, we continued to demonstrate the capability of our treatment solutions to address the most challenging wastewater pain points. Here are a few 2020 highlights you may have missed:
System Commissioning: We commissioned a new system at an animal health plant in the U.S. Midwest that treats an antiparasitic API in rinse water so the treated water can be safely discharged. The Axine system eliminates off-site trucking and incineration, which had caused periodic site bottlenecks. Our solution reduces site operating costs, eliminates more than 20,000 miles of trucking per year, and reduces greenhouse gas emissions.
Pharma Service Agreement: We signed a master service agreement with a global pharmaceutical company and are implementing a first project to treat rinse water from a new production line at one of their manufacturing sites on the U.S. East Coast. The Axine system will treat an antimicrobial API in rinse water, which enables the site to achieve its API Predicted No-Effect Concentration (PNEC) goals while eliminating the need for off-site disposal.
Pharma Service Agreement: We also signed a master service agreement with a U.S. pharma company to develop a wastewater treatment system at a manufacturing site in the Northeastern U.S. The Axine system will treat up to 15 different APIs in rinse water to ensure the site meets its API PNEC targets before discharge. After completion of field piloting, we will move to full-scale installation.
System Commissioning: We opened a 10,000 square foot assembly facility in Metro Vancouver to manufacture, assemble, and test wastewater systems before shipment to customer sites. The new facility helps meet growing demand for Axine systems worldwide and accommodates our expanding engineering and operations team. Stay tuned for some exciting news in January about strategic hires we’ve made to help us expand into new international markets.
Industry Participation: Axine CEO Jonathan Rhone participated in a variety of online technical and industry events including a webinar organized by the Pharmaceutical Supply Chain Initiative (PSCI) where he joined representatives from Merck and Johnson & Johnson to discuss technology options, solutions, and case studies for treating pharmaceutical manufacturing wastewater.
Industry Recognition: To cap off the year, Axine was named to the 2021 Global Cleantech 100 List for the sixth time recognizing the impact of our industrial wastewater treatment solutions.
Axine’s team is excited to build on the momentum from 2020 by continuing to scale-up, expand, and achieve new milestones in technology, applications, sales, and service in 2021. Expect to see a regular flow of important news as we work to conquer the toughest industrial wastewater.
We hope you found this helpful. Please let us know if you have any questions or project inquiries. You can also follow us on LinkedIn to stay up to date on our technology and project progress.